{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:11Z","timestamp":1786979891971,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07176-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:04:53Z","timestamp":1742425493000},"page":"3180-3189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials"],"prefix":"10.1007","volume":"52","author":[{"given":"Sol\u00e8ne","family":"Malmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mad-Helenie","family":"Elsensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Le","family":"Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine Al","family":"Tabaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Bland","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Vija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Kanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-4564","authenticated-orcid":false,"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"7176_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/hon.2227","volume":"33","author":"ASBS Cottereau","year":"2015","unstructured":"Cottereau ASBS, Broussais, Casasnovas O, Kanoun S, Roques M, Charrier N, Bertrand S, Delarue R, Bonnet C, Hustinx R, Gaulard P, de Leval L, Vera P, tti E, Mounier N, Haioun C, Tilly H, Meignan M. Pronostic value of baseline metabolic tumor volume (MTV0) measured on FDG PET\/CT in patients with peripheral T-cell lymphoma (PTCL), 13-ICML oral presentations. Hematol Oncol. 2015;33:100\u201380. https:\/\/doi.org\/10.1002\/hon.2227.","journal-title":"Hematol Oncol"},{"key":"7176_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2825","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B cell lymphoma. Clin cancer Research: Official J Am Association Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2825.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"7176_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in High-Tumor-Burden follicular lymphoma: A pooled analysis of three multicenter studies. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34:3618\u201326. https:\/\/doi.org\/10.1200\/JCO.2016.66.9440.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7176_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","volume":"126","author":"L Ceriani","year":"2015","unstructured":"Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, et al. Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950\u20136. https:\/\/doi.org\/10.1182\/blood-2014-12-616474.","journal-title":"Blood"},{"key":"7176_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3315-7","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, Moller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016. https:\/\/doi.org\/10.1007\/s00259-016-3315-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","volume":"124","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Huttmann A, Muller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.027.","journal-title":"Eur J Cancer"},{"key":"7176_CR7","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, et al. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 2022;107:1633\u201342. https:\/\/doi.org\/10.3324\/haematol.2021.278663.","journal-title":"Haematologica"},{"key":"7176_CR8","doi-asserted-by":"publisher","unstructured":"Meignan M, Cottereau AS, Specht L, Mikhaeel NG. Total tumor burden in lymphoma - an evolving strong prognostic parameter. Br J Radiol. 2021;20210448. https:\/\/doi.org\/10.1259\/bjr.20210448.","DOI":"10.1259\/bjr.20210448"},{"key":"7176_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2805","author":"E Zucca","year":"2020","unstructured":"Zucca E, Cascione L, Ruberto T, Facchinelli D, Schar S, Hayoz S, et al. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-Cell lymphoma: Post-Hoc analysis from the SAKK38\/07 clinical trial. Hematol Oncol. 2020. https:\/\/doi.org\/10.1002\/hon.2805.","journal-title":"Hematol Oncol"},{"key":"7176_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2016.01.010","volume":"42","author":"MK Song","year":"2016","unstructured":"Song MK, Yang DH, Lee GW, Lim SN, Shin S, Pak KJ, et al. High total metabolic tumor volume in PET\/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk Res. 2016;42:1\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2016.01.010.","journal-title":"Leuk Res"},{"key":"7176_CR11","doi-asserted-by":"publisher","unstructured":"Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schar S, et al. Integration of baseline metabolic parameters and mutational profiles predicts Long-Term response to First-Line therapy in DLBCL patients: A post hoc analysis of the SAKK38\/07 study. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14041018.","DOI":"10.3390\/cancers14041018"},{"key":"7176_CR12","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, Duhrsen U, et al. Proposed new dynamic prognostic index for diffuse large B-Cell lymphoma: international metabolic prognostic index. J Clin Oncol. 2022;40:2352\u201360. https:\/\/doi.org\/10.1200\/JCO.21.02063.","journal-title":"J Clin Oncol"},{"key":"7176_CR13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s00259-019-04286-8","volume":"46","author":"L Ceriani","year":"2019","unstructured":"Ceriani L, Milan L, Johnson PWM, Martelli M, Presilla S, Giovanella L, et al. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. Eur J Nucl Med Mol Imaging. 2019;46:1334\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04286-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719\u201324. https:\/\/doi.org\/10.1093\/annonc\/mdw011.","journal-title":"Ann Oncol"},{"key":"7176_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on Phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322. https:\/\/doi.org\/10.1007\/s00259-014-2705-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR16","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, et al. Prognostic value of baseline metabolic tumor volume in early-stage hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456\u201363. https:\/\/doi.org\/10.1182\/blood-2017-07-795476.","journal-title":"Blood"},{"key":"7176_CR17","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135:1396\u2013405. https:\/\/doi.org\/10.1182\/blood.2019003526.","journal-title":"Blood"},{"key":"7176_CR18","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36:2845\u201353. https:\/\/doi.org\/10.1200\/JCO.2018.78.5246.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7176_CR19","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Schoder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory hodgkin lymphoma. Blood. 2017;130:2196\u2013203. https:\/\/doi.org\/10.1182\/blood-2017-06-788877.","journal-title":"Blood"},{"key":"7176_CR20","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1182\/bloodadvances.2021006923","volume":"6","author":"C Thieblemont","year":"2022","unstructured":"Thieblemont C, Chartier L, Duhrsen U, Vitolo U, Barrington SF, Zaucha JM, et al. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Adv. 2022;6:5995\u20136004. https:\/\/doi.org\/10.1182\/bloodadvances.2021006923.","journal-title":"Blood Adv"},{"key":"7176_CR21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735\u201343. https:\/\/doi.org\/10.1007\/s00259-014-2783-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.annonc.2023.10.121","volume":"35","author":"AS Cottereau","year":"2024","unstructured":"Cottereau AS, Rebaud L, Trotman J, Feugier P, Nastoupil LJ, Bachy E, et al. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial. Ann Oncol. 2024;35:130\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.121.","journal-title":"Ann Oncol"},{"key":"7176_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","volume":"45","author":"MN Toledano","year":"2018","unstructured":"Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, et al. Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:680\u20138. https:\/\/doi.org\/10.1007\/s00259-017-3907-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60:1096\u2013102. https:\/\/doi.org\/10.2967\/jnumed.119.227249.","journal-title":"Soc Nuclear Med"},{"key":"7176_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2967\/jnumed.123.267022","volume":"65","author":"SF Barrington","year":"2024","unstructured":"Barrington SF, Cottereau AS, Zijlstra JM. Is (18)F-FDG metabolic tumor volume in lymphoma really happening?? J Nucl Med. 2024;65:510\u20131. https:\/\/doi.org\/10.2967\/jnumed.123.267022.","journal-title":"J Nucl Med"},{"key":"7176_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen B, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-Cell lymphoma: which method is most successful?? A study on behalf of the PETRA consortium. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2021;62:332\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.238923.","journal-title":"Soc Nuclear Med"},{"key":"7176_CR28","doi-asserted-by":"publisher","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L et al. International benchmark for total metabolic tumor volume measurement in baseline (18)F-FDG PET\/CT of lymphoma patients: A milestone toward clinical implementation. Journal of nuclear medicine: official publication, society of nuclear medicine. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.267789","DOI":"10.2967\/jnumed.124.267789"},{"key":"7176_CR29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2967\/jnumed.121.263067","volume":"63","author":"J Driessen","year":"2022","unstructured":"Driessen J, Zwezerijnen GJC, Schoder H, Drees EEE, Kersten MJ, Moskowitz AJ, et al. The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in (18)F-FDG PET scans of patients with classical hodgkin lymphoma. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:1424\u201330. https:\/\/doi.org\/10.2967\/jnumed.121.263067.","journal-title":"Soc Nuclear Med"},{"key":"7176_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","volume":"22","author":"L van Heek","year":"2022","unstructured":"van Heek L, Stuka C, Kaul H, Muller H, Mettler J, Hitz F, et al. Predictive value of baseline metabolic tumor volume in early-stage favorable hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC Cancer. 2022;22:672. https:\/\/doi.org\/10.1186\/s12885-022-09758-z.","journal-title":"BMC Cancer"},{"key":"7176_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2967\/jnumed.124.268874","volume":"66","author":"L Ceriani","year":"2025","unstructured":"Ceriani L, Milan L, Pirosa MC, Martelli M, Ruberto T, Cascione L, et al. PET-Based risk stratification in primary mediastinal B-Cell lymphoma: A comparative analysis of different segmentation methods in the IELSG37 trial patient cohort. J Nucl Med. 2025;66:209\u201314. https:\/\/doi.org\/10.2967\/jnumed.124.268874.","journal-title":"J Nucl Med"},{"key":"7176_CR32","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","volume":"35","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-Cell lymphoma treated with First-Line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35:2473\u201381. https:\/\/doi.org\/10.1200\/JCO.2017.72.6984.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7176_CR33","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2020008750","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Ghesquieres H, Oberic L, Morschhauser F, Tilly H, Ribrag V, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137:2307\u201320. https:\/\/doi.org\/10.1182\/blood.2020008750.","journal-title":"Blood"},{"key":"7176_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus Lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1805104.","journal-title":"N Engl J Med"},{"key":"7176_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20:202\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30784-8.","journal-title":"Lancet Oncol"},{"key":"7176_CR36","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in hodgkin lymphoma. PLoS ONE. 2015;10:e0140830. https:\/\/doi.org\/10.1371\/journal.pone.0140830.","journal-title":"PLoS ONE"},{"key":"7176_CR37","doi-asserted-by":"publisher","first-page":"e069249","DOI":"10.1136\/bmj-2021-069249","volume":"377","author":"N van Geloven","year":"2022","unstructured":"van Geloven N, Giardiello D, Bonneville EF, Teece L, Ramspek CL, van Smeden M, et al. Validation of prediction models in the presence of competing risks: a guide through modern methods. BMJ. 2022;377:e069249. https:\/\/doi.org\/10.1136\/bmj-2021-069249.","journal-title":"BMJ"},{"key":"7176_CR38","unstructured":"Gerds TOJ, Ozenne B. Risk Regression Models and Prediction Scores for Survival Analysis with Competing Risks. R package version 2023.12.21. https:\/\/cran.r-project.org\/web\/packages\/riskRegression\/riskRegression.pdf"},{"key":"7176_CR39","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1038\/s41598-024-58412-0","volume":"14","author":"S Draye-Carbonnier","year":"2024","unstructured":"Draye-Carbonnier S, Camus V, Becker S, Tonnelet D, Leveque E, Zduniak A, et al. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma. Sci Rep. 2024;14:8033. https:\/\/doi.org\/10.1038\/s41598-024-58412-0.","journal-title":"Sci Rep"},{"key":"7176_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, et al. (18)F-FDG PET dissemination features in diffuse large B-Cell lymphoma are predictive of outcome. J Nucl Med. 2020;61:40\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.229450.","journal-title":"J Nucl Med"},{"key":"7176_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(dagger). Ann Oncol. 2021;32:404\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.019.","journal-title":"Ann Oncol"},{"key":"7176_CR42","doi-asserted-by":"publisher","first-page":"1515040","DOI":"10.3389\/fmed.2024.1515040","volume":"11","author":"D Albano","year":"2024","unstructured":"Albano D, Ravanelli M, Durmo R, Versari A, Filice A, Rizzo A, et al. Semiquantitative 2-[(18)F]FDG PET\/CT-based parameters role in lymphoma. Front Med (Lausanne). 2024;11:1515040. https:\/\/doi.org\/10.3389\/fmed.2024.1515040.","journal-title":"Front Med (Lausanne)"},{"key":"7176_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13550-022-00916-9","volume":"12","author":"MC Ferrandez","year":"2022","unstructured":"Ferrandez MC, Eertink JJ, Golla SSV, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, et al. Combatting the effect of image reconstruction settings on lymphoma [(18)F]FDG PET metabolic tumor volume assessment using various segmentation methods. EJNMMI Res. 2022;12:44. https:\/\/doi.org\/10.1186\/s13550-022-00916-9.","journal-title":"EJNMMI Res"},{"key":"7176_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2967\/jnumed.121.262464","volume":"63","author":"F Orlhac","year":"2022","unstructured":"Orlhac F, Eertink JJ, Cottereau AS, Zijlstra JM, Thieblemont C, Meignan M, et al. A guide to combat harmonization of imaging biomarkers in multicenter studies. J Nucl Med. 2022;63:172\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262464.","journal-title":"J Nucl Med"},{"key":"7176_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, et al. A postreconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med. 2018;59:1321\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.199935.","journal-title":"J Nucl Med"},{"key":"7176_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40644-022-00476-0","volume":"22","author":"S Jemaa","year":"2022","unstructured":"Jemaa S, Paulson JN, Hutchings M, Kostakoglu L, Trotman J, Tracy S, et al. Full automation of total metabolic tumor volume from FDG-PET\/CT in DLBCL for baseline risk assessments. Cancer Imaging. 2022;22:39. https:\/\/doi.org\/10.1186\/s40644-022-00476-0.","journal-title":"Cancer Imaging"},{"key":"7176_CR47","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s00259-020-05080-7","volume":"48","author":"P Blanc-Durand","year":"2021","unstructured":"Blanc-Durand P, Jegou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodere F, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET\/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2021;48:1362\u201370. https:\/\/doi.org\/10.1007\/s00259-020-05080-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7176_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40658-020-00346-3","volume":"7","author":"AJ Weisman","year":"2020","unstructured":"Weisman AJ, Kim J, Lee I, McCarten KM, Kessel S, Schwartz CL, et al. Automated quantification of baseline imaging PET metrics on FDG PET\/CT images of pediatric hodgkin lymphoma patients. EJNMMI Phys. 2020;7:76. https:\/\/doi.org\/10.1186\/s40658-020-00346-3.","journal-title":"EJNMMI Phys"},{"key":"7176_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/cpf.12868","volume":"44","author":"M Sadik","year":"2024","unstructured":"Sadik M, Barrington SF, Tragardh E, Saboury B, Nielsen AL, Jakobsen AL, et al. Metabolic tumour volume in hodgkin lymphoma-A comparison between manual and AI-based analysis. Clin Physiol Funct Imaging. 2024;44:220\u20137. https:\/\/doi.org\/10.1111\/cpf.12868.","journal-title":"Clin Physiol Funct Imaging"},{"key":"7176_CR50","doi-asserted-by":"publisher","unstructured":"Revailler W, Cottereau AS, Rossi C, Noyelle R, Trouillard T, Morschhauser F, et al. Deep learning approach to automatize TMTV calculations regardless of segmentation methodology for major FDG-Avid lymphomas. Diagnostics (Basel). 2022;12. https:\/\/doi.org\/10.3390\/diagnostics12020417.","DOI":"10.3390\/diagnostics12020417"},{"key":"7176_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.120.242412","volume":"62","author":"N Capobianco","year":"2021","unstructured":"Capobianco N, Meignan M, Cottereau AS, Vercellino L, Sibille L, Spottiswoode B, et al. Deep-Learning (18)F-FDG uptake classification enables total metabolic tumor volume Estimation in diffuse large B-Cell lymphoma. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2021;62:30\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.242412.","journal-title":"Soc Nuclear Med"},{"key":"7176_CR52","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","volume":"63","author":"KB Girum","year":"2022","unstructured":"Girum KB, Rebaud L, Cottereau AS, Meignan M, Clerc J, Vercellino L, et al. (18)F-FDG PET Maximum-Intensity projections and artificial intelligence: A Win-Win combination to easily measure prognostic biomarkers in DLBCL patients. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:1925\u201332. https:\/\/doi.org\/10.2967\/jnumed.121.263501.","journal-title":"Soc Nuclear Med"},{"key":"7176_CR53","doi-asserted-by":"publisher","first-page":"13111","DOI":"10.1038\/s41598-023-40218-1","volume":"13","author":"MC Ferrandez","year":"2023","unstructured":"Ferrandez MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, et al. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci Rep. 2023;13:13111. https:\/\/doi.org\/10.1038\/s41598-023-40218-1.","journal-title":"Sci Rep"},{"key":"7176_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-023-01036-8","volume":"13","author":"MC Ferrandez","year":"2023","unstructured":"Ferrandez MC, Golla SSV, Eertink JJ, de Vries BM, Wiegers SE, Zwezerijnen GJC, et al. Sensitivity of an AI method for [(18)F]FDG PET\/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols. EJNMMI Res. 2023;13:88. https:\/\/doi.org\/10.1186\/s13550-023-01036-8.","journal-title":"EJNMMI Res"},{"key":"7176_CR55","doi-asserted-by":"publisher","first-page":"e081554","DOI":"10.1136\/bmj-2024-081554","volume":"388","author":"K Lekadir","year":"2025","unstructured":"Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025;388:e081554. https:\/\/doi.org\/10.1136\/bmj-2024-081554.","journal-title":"BMJ"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07176-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07176-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07176-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:52:19Z","timestamp":1751421139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07176-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7176"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07176-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study, as part of prospective trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors have no relevant financial or non-financial interests to disclose directly related to this work. The authors have the following disclosure, indirectly related to this work to declare: Solene Malmon: no conflicts of interest to disclose. Mad-Helenie Elsensohn: no conflicts of interest to disclose. Catherine Thieblemont. Franck Morschhauser: consultancy: Roche\/Genentech; consultancy and membership on an entity\u2019s Board of Directors or advisory committees: Kite\/Gilead Sciences, Bristol Myers Squibb, AbbVie, Epizyme, AstraZeneca, Novartis, Genmab; honoraria: Roche\/Genentech, Chugai, Takeda. Olivier Casasnovas: consultancy: Roche\/Genentech, BMS, Takeda, MSD, Gilead, ADC therapeutics; Research funding: Roche\/Genentech, Gilead; honoraria: Roche\/Genentech, Takeda, MSD, Abbvie, Beigene. Marc Andr\u00e9. Steven Le Gouill. Yassin Altabaa: no conflicts of interest to disclose. Paul Bland Durand: co-founder of PAIRE, consultancy: Pfizer, PAIRE. Clement Bailly: no conflicts of interest to disclose. Veronique Edeline. Lavinia Vija: no conflicts of interest to disclose related to this work. Laetitia Vercellino: consultancy: Kite Gilead, Genmab; hospitality from MSD France, Siemens Healthcare and Sanofi Aventis. Romain Ricci: no conflicts of interest to disclose.Salim Kanoun Salim Kanoun: is the founder of the Pixilib imaging CRO. AS Cottereau: no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}